Lymphadenopathy resident survival guide: Difference between revisions
/* Differential diagnosis and management{{cite journal |vauthors=Ferrer R |title=Lymphadenopathy: differential diagnosis and evaluation |journal=Am Fam Physician |volume=58 |issue=6 |pages=1313–20 |date=October 1998 |pmid=9803196 |doi= |url=}}{{cite journal |vauthors=Bazemore AW, Smucker DR |title=Lymphadenopathy and malignancy |journal=Am Fam Physician |volume=66 |issue=11 |pages=2103–10 |date=December 2002 |pmid=12484692 |doi= |url=}}{{cite journal |vauthors=Kiran KU, Krishna Moorthy KV, Me... |
|||
Line 204: | Line 204: | ||
6. [[Skin cancer]] | 6. [[Skin cancer]] | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | ||
#[[Leprosy medical therapy|Leprosy]], [[Mycobacterium bovis#Treatment|mycobacterium bovis infection]], [[Tuberculosis medical therapy|TB]] | # [[Leprosy medical therapy|Leprosy]], [[Mycobacterium bovis#Treatment|mycobacterium bovis infection]], [[Tuberculosis medical therapy|TB]] | ||
#Fungal infections-topical antifungals | # Fungal infections-topical antifungals | ||
#[[Kikuchi disease medical therapy|Kikuchi disease]] | # [[Kikuchi disease medical therapy|Kikuchi disease]] | ||
#Lymphoma: [[Non-Hodgkin lymphoma medical therapy|Non-Hodgkin lymphoma]], [[Hodgkin's lymphoma medical therapy|Hodgkin's lymphoma]] | # Lymphoma: [[Non-Hodgkin lymphoma medical therapy|Non-Hodgkin lymphoma]], [[Hodgkin's lymphoma medical therapy|Hodgkin's lymphoma]] | ||
#[[Squamous cell carcinoma of the skin medical therapy|Squamous cell carcinoma]] | #[[Squamous cell carcinoma of the skin medical therapy|Squamous cell carcinoma]] | ||
#[[Skin cancer#Treatment|Skin cancer]] | #[[Skin cancer#Treatment|Skin cancer]] | ||
|- | |- | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Submandibular]] and [[Lymph node#Distribution|anterior cervical]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Submandibular]] and [[Lymph node#Distribution|anterior cervical]] | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |[[URTI]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Squamous cell carcinoma]] (head and neck), [[ | #[[URTI]] | ||
# [[Infectious mononucleosis]] (IM or mononucleosis) | |||
#[[CMV]] [[odontogenic infection]] | |||
# [[Rubella]] | |||
# [[Toxoplasmosis]] | |||
# [[Mycobacterium|Mycobacterial infection]] | |||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | |||
7. [[Lymphoma]]<br> | |||
8. [[Squamous cell carcinoma]] (head and neck)<br> | |||
9. [[Leukemia]]s: [[Acute myeloid leukemia|AML]], [[Acute lymphoblastic leukemia|ALL]], [[Chronic lymphocytic leukemia|CLL]], [[Chronic myelogenous leukemia|CML]] <br> | |||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | ||
#[[Upper respiratory tract infection medical therapy|URTI]] | |||
# [[Mononucleosis medical therapy|Mononucleosis]] | |||
# [[Odontogenic infection#Treatment|Odontogenic infection]] | |||
# [[Rubella medical therapy|Rubella]] | |||
# [[Toxoplasmosis medical therapy|Toxoplasmosis]] | |||
#[[Leprosy medical therapy|Leprosy]], [[Mycobacterium bovis#Treatment|mycobacterium bovis infection]], [[Tuberculosis medical therapy|TB]] | |||
# Lymphoma: [[Non-Hodgkin lymphoma medical therapy|Non-Hodgkin lymphoma]], [[Hodgkin's lymphoma medical therapy|Hodgkin's lymphoma]] | |||
#[[Squamous cell carcinoma of the skin medical therapy|Squamous cell carcinoma]] | |||
# [[Leukemia]]s: [[Acute myeloid leukemia|AML]], [[Acute lymphoblastic leukemia|ALL]], [[Chronic lymphocytic leukemia|CLL]], [[Chronic myelogenous leukemia|CML]] | |||
|- | |- | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Lymph node#Distribution|Supraclavicular]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Lymph node#Distribution|Supraclavicular]] | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | ||
#[[Mycobacterium|Mycobacterial infection]] | |||
#[[Mycosis]] | |||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | |||
3. [[Breast cancer]]<br> | |||
4. [[Lung cancer]]<br> | |||
5. [[Esophageal cancer]]<br> | |||
6. [[Mediastinal tumor|mediastinal cancer]]<br> | |||
7. [[Stomach cancer]] ([[Virchow's node]])<br> | |||
8. [[Laryngeal cancer]]<br> | |||
9. [[Thyroid cancer]] ([[papillary thyroid cancer|papillary]], [[medullary thyroid cancer|medullary]],[[follicular thyroid cancer|follicular]], and [[anaplastic thyroid cancer|anaplastic]]) | |||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | |||
# [[Leprosy medical therapy|Leprosy]], [[Mycobacterium bovis#Treatment|mycobacterium bovis infection]], [[Tuberculosis medical therapy|TB]] | |||
# [[Mycosis*Treatment|Mycosis]] | |||
# [[Breast cancer treatment|Breast cancer]] | |||
# [[Lung cancer medical therapy|Lung cancer]] | |||
# [[Esophageal cancer medical therapy|Esophageal cancer]] | |||
# [[Mediastinal tumor medical therapy|Mediastinal cancer]] | |||
# [[Stomach cancer medical therapy|Stomach cancer]] | |||
# [[Laryngeal cancer medical therapy|Laryngeal cancer ]] | |||
# [[Thyroid cancer]]: [[Papillary thyroid cancer medical therapy|oapillary thyroid cancer]], [[Medullary thyroid cancer medical therapy|medullary thyroid cancer]], [[Follicular thyroid cancer medical therapy|follicular thyroid cancer]] and [[Anaplastic thyroid cancer medical therapy|anaplastic thyroid cancer]] | |||
|- | |- | ||
| rowspan="3" style="width: 10px; background: #4479BA;" | Axillary | | rowspan="3" style="width: 10px; background: #4479BA;" | Axillary | ||
Line 229: | Line 265: | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Lymph node#Distribution|Axillary]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Lymph node#Distribution|Axillary]] | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Secondary [[syphilis]], [[sarcoidosis]], [[Cat-scratch disease]], [[tularemia]],[[leprosy]], [[leishmaniasis]], [[brucellosis]], [[sporotrichosis]], [[skin infection]]/ skin [[trauma]], [[breast infections]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Secondary [[syphilis]], [[sarcoidosis]], [[Cat-scratch disease]], [[tularemia]],[[leprosy]], [[leishmaniasis]], [[brucellosis]], [[sporotrichosis]], [[skin infection]]/ skin [[trauma]], [[breast infections]] | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Breat [[adenocarcinoma]], [[lymphoma]], [[leukemia]], [[Kaposi sarcoma]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Breat [[adenocarcinoma]], [[lymphoma]], | ||
#Leukemias: [[Acute myeloid leukemia medical therapy|AML]], [[Acute lymphoblastic leukemia medical therapy|ALL]], [[Chronic lymphocytic leukemia medical therapy|CLL]], [[Chronic myelogenous leukemia medical therapy|CML]] | |||
#[[Kaposi sarcoma]] | |||
#[[Skin cancer]] | |||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | ||
#Leukemias: [[Acute myeloid leukemia medical therapy|AML]], [[Acute lymphoblastic leukemia medical therapy|ALL]], [[Chronic lymphocytic leukemia medical therapy|CLL]], [[Chronic myelogenous leukemia medical therapy|CML]] | |||
[[Erysipelas medical therapy|Erysipelas]], [[Cellulitis medical therapy|cellulitis]] | [[Erysipelas medical therapy|Erysipelas]], [[Cellulitis medical therapy|cellulitis]] | ||
|- | |- | ||
Line 240: | Line 280: | ||
3. [[Skin cancer]]<br> | 3. [[Skin cancer]]<br> | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | ||
# [[Erysipelas medical therapy|Erysipelas]] (in addition to [[antibiotics]], [[bed rest]], leg elevation, and administration of [[anticoagulants]] among patients at risk of [[venous thromboembolism]]) and [[Cellulitis medical therapy|cellulitis]]<br> | |||
# Lymphoma: [[Non-Hodgkin lymphoma medical therapy|Non-Hodgkin lymphoma]], [[Hodgkin's lymphoma medical therapy|Hodgkin's lymphoma]] | |||
#[[Skin cancer#Treatment|Skin cancer]] | |||
|- | |- | ||
| rowspan="3" style="width: 100px; background: #4479BA;" | [[Lymph node#Distribution|Superficial inguinal]] | | rowspan="3" style="width: 100px; background: #4479BA;" | [[Lymph node#Distribution|Superficial inguinal]] |
Revision as of 14:24, 25 August 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Javaria Anwer M.D.[2]
Synonyms and keywords: lymphadenopathy management guide, lymph node pathology management guide
Lymphadenopathy resident survival guide microchapters |
---|
Overview |
Causes |
Management |
Do's |
Don'ts |
Overview
Lymphadenopathy (LAD) is used to describe abnormal size, consistency, and the number of lymph nodes. Under normal conditions, lymph nodes may not be palpated. The lymph nodes maybe central or peripheral located deep in the subcutaneous tissue. Common causes of lymphadenopathy include infectious and non-infectious. A thorough physical exam is important to establish a differential diagnosis.
Causes
Life Threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- Infectious mediastinal lymphadenopathy[1]
Common Causes
The American Academy of Family Physicians (AAFP) and many research articles utilize a pneumonic CHICAGO to include all causes of lymphadenopathy based on etiology.[2][3] The causes may also be remembered based on the location of lymph nodes.
- Cancers:
- Hypersensitivity :
- Serum sickness, immunization reactions, graft-vs-host disease, silicone allergy, and drug allergy (such as sulfonamides, allopurinol, carbamazepine, etc).
- Infections:
- Fungal, Protozoan, Rickettsial (Typhus), Helminthes.
- Bacterial: Tiberculosis, syphilis (primary and secondary), chancroid, staphylococcus or streptococcal skin infections.
- Viral: IM, CMV, HIV,lymphadenitis post vaccination, adenovirus, herpes zoster, and hepatitis (infectious), and melioidosis.
- Chlamydial (lymphogranuloma venereum), protozoan (toxoplasmosis), mycotic (histoplasmosis, coccidioidomycosis, helminthic (filariasis, and rickettsial (typhus).
- Connective tissue disorders:
- Atypical lymphoproliferative disorders :
- Granulomatous:
- Others:
- Rosai Dorfman disease, Kikuchi disease, pseudotumor of L.N, transformation of germinal centers, and vascular transformation of sinuses.
- For more detailed information in the causes of lymphadenopathy, click here.
Management
Diagnostic algorithm and management
The algorithm illustrates the approach to management of lymphadenopathy[4][5][6][7][8]. Borrowed from:[9][10][11]
.History
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Physical exam Appearance of the patient Cachexia or surgical scar marks demonstrating previous malignancy treatment
❑ HEENT
❑ Extremities exam | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Palpable lymph node ❑ Location: (Localized vs generalized)
❑ Dimensions
❑ Tenderness or pain:
❑ Consistency
❑ Mobility
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Labs ❑ CBC with differential
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnostic of self-limiting or benign disease Pharyngitis, URTI, conjunctivitis, cat-scratch disease, etc | Suggests infection/ serious infection | Unexplained | Suggests malignancy | ||||||||||||||||||||||||||||||||||||||||||||||||||
May require specific tests | Perform specific tests ❑ IM: Heterophile Antibody and monospot test | Risk factors for malignancy Family history, age, exposure, etc | Perform specific tests | ||||||||||||||||||||||||||||||||||||||||||||||||||
Excisional biopsy | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Positive | Negative | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Negative | Positive | ||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Treat ❑ To read about the treatment of strept throat, click here | Staging | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Treat | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Low risk | High risk | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Specific tests/ biopsy | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Localized | Generalized | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Review history and clues suggesting malignancy | Review history and clues suggesting malignancy | Positive | Treat | ||||||||||||||||||||||||||||||||||||||||||||||||||
Negative | |||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Specific tests such as CXR, ultrasound, CT, lab workup, biopsy. ❑ The US findings that help differentiate benign lAD from malignant include:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Observe 3-4 weeks | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Undiagnostic | Diagnostic | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Progress/persists | Regress | ||||||||||||||||||||||||||||||||||||||||||||||||||||
No follow-up | Biopsy | Treatment | |||||||||||||||||||||||||||||||||||||||||||||||||||
Positive | Negative | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Staging | Follow-up | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Biopsy | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Negative | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Positive | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Staging | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Differential diagnosis and management[10][11][12][13]
For detailed information on the neck lymphadenopathy and its diagnostic findings click here
Do's
- Patients with immunodeficiency should have a wide differential diagnosis considering non-Hodgkin's lymphoma and Kaposi sarcoma.[11]
- Remember that lymphadenopathy involving supraclavicular L.N poses the highest risk of malignancy (90% among patients >40 years of age) and 25% among < 40 years old. [14]
Don'ts
- Physical examination should never be missed as a finding may change the course of differential diagnosis. Missing the physical exam may lead to unnecessary investigations and delays.[4]
- Needle aspiration biopsy or excisional biopsy is the gold standard for the tissue diagnosis and evaluation for lymphadenopathy.[9]
References
- ↑ Hiraishi Y, Goto Y, Ohishi N, Nagase T (May 2013). "Infectious mediastinal lymphadenopathy after repeated transbronchial needle aspiration". BMJ Case Rep. 2013. doi:10.1136/bcr-2012-007998. PMC 3669807. PMID 23723103.
- ↑ "Tips From Other Journals - American Family Physician".
- ↑ Habermann TM, Steensma DP (July 2000). "Lymphadenopathy". Mayo Clin. Proc. 75 (7): 723–32. doi:10.4065/75.7.723. PMID 10907389.
- ↑ 4.0 4.1 Garg PK, Jain BK, Dubey IB, Sharma AK (2013). "Generalized lymphadenopathy: physical examination revisited". Ann Saudi Med. 33 (3): 298–300. doi:10.5144/0256-4947.2012.01.7.1525. PMC 6078537. PMID 22750769.
- ↑ Soldes OS, Younger JG, Hirschl RB (October 1999). "Predictors of malignancy in childhood peripheral lymphadenopathy". J. Pediatr. Surg. 34 (10): 1447–52. doi:10.1016/s0022-3468(99)90101-x. PMID 10549745.
- ↑ Ghirardelli ML, Jemos V, Gobbi PG (March 1999). "Diagnostic approach to lymph node enlargement". Haematologica. 84 (3): 242–7. PMID 10189390.
- ↑ Ramadas AA, Jose R, Varma B, Chandy ML (2017). "Cervical lymphadenopathy: Unwinding the hidden truth". Dent Res J (Isfahan). 14 (1): 73–78. doi:10.4103/1735-3327.201136. PMC 5356393. PMID 28348622.
- ↑ Wilson, Adrian (2008). "Pharyngitis": 15–24. doi:10.1007/978-1-60327-034-2_2.
- ↑ 9.0 9.1 Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A (March 2014). "Peripheral lymphadenopathy: approach and diagnostic tools". Iran J Med Sci. 39 (2 Suppl): 158–70. PMC 3993046. PMID 24753638.
- ↑ 10.0 10.1 Ferrer R (October 1998). "Lymphadenopathy: differential diagnosis and evaluation". Am Fam Physician. 58 (6): 1313–20. PMID 9803196.
- ↑ 11.0 11.1 11.2 Bazemore AW, Smucker DR (December 2002). "Lymphadenopathy and malignancy". Am Fam Physician. 66 (11): 2103–10. PMID 12484692.
- ↑ Kiran KU, Krishna Moorthy KV, Meher V, Rao PN (2009). "Relapse of leprosy presenting as nodular lymph node swelling". Indian J Dermatol Venereol Leprol. 75 (2): 177–9. doi:10.4103/0378-6323.48666. PMID 19293508.
- ↑ Bonnetblanc JM, Bédane C (2003). "Erysipelas: recognition and management". Am J Clin Dermatol. 4 (3): 157–63. doi:10.2165/00128071-200304030-00002. PMID 12627991.
- ↑ Fijten GH, Blijham GH (October 1988). "Unexplained lymphadenopathy in family practice. An evaluation of the probability of malignant causes and the effectiveness of physicians' workup". J Fam Pract. 27 (4): 373–6. doi:10.1080/09503158808416945. PMID 3049914.